Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2011 / Cilt: 45 - Sayı: 2

Prophylactic antiviral treatment in recurrent herpes zoster: a case report

Rekürren herpes zoster olgusunda profilaktik antiviral tedavi

Pages
111–114
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We think that prophylactic antiviral therapy should be initiated in immunosuppressive individuals who have recurrent herpes zoster attacks.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Herpes zoster (HZ) occurs in older ages with activation of varicella-zoster virus (VZV) which persists in a dormant phase within the dorsal root ganglia.
📊
Key Findings & Data:The incidence of HZ in immunosuppressed patients is 20-100 times higher and the clinical progress is more severe than in immunocompetent individuals.
💡
Conclusion & Impact:We think that prophylactic antiviral therapy should be initiated in immunosuppressive individuals who have recurrent herpes zoster attacks.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Herpes zoster (HZ) occurs in older ages with activation of varicella-zoster virus (VZV) which persists in a dormant phase within the dorsal root ganglia. The incidence of HZ in immunosuppressed patients is 20-100 times higher and the clinical progress is more severe than in immunocompetent individuals. A 48-year-old man who had been diagnosed with acute myelocytic leukemia type M3 and had been treated with immunosuppressive agents was admitted to our clinic. The patient was clinically diagnosed as having HZ. He was treated with acyclovir 800 mg five times daily for 7 days. In the consecutive three months, he attended our clinic again with similar complaints. The left cervical (C)5, C6 dermatomes were involved at the fourth attack of HZ. Multinucleated giant cells were determined on the Tzanck smear. VZV DNA was detected by polymerase chain reaction (PCR). Treatment with valacyclovir 1 g three times daily for 14 days was prescribed and then, prophylactic treatment with valacyclovir 500 mg two times a day was administered. Although immunosuppressive treatment was continued, no new attacks of herpes zoster occurred. We think that prophylactic antiviral therapy should be initiated in immunosuppressive individuals who have recurrent herpes zoster attacks.

Özet

Herpes zoster (HZ); sıklıkla yaşamın ilerleyen dönemlerinde, arka kök ganglionlarında eylemsiz halde bulunan varisella zoster virüsü (VZV)'nün aktifleşmesi ile ortaya çıkar. Bağışıklık sistemi baskılanmış hastalarda HZ insidansı 20-100 kat kadar artmıştır ve daha şiddetli seyretmektedir. Akut myelositik lösemi (AML) tip M3 tanısıyla immunsupresif tedavi uygulanan 48 yaşında erkek hasta polikliniğimize başvurdu. Hastaya klinik olarak HZ tanısı konuldu. Asiklovir 5x800 mg/gün ile HZ tedavisi yapıldı. Hasta ardışık olarak 3 ay üst üste benzer şikayetlerle tekrar başvurdu. Hastanın dördüncü herpes zoster atağında sol servikal (C)5, C6 dermatom alanları tutulmuştu. Tzanck yaymada multinükleer dev hücreler izlendi. Vezikülden alınan örnekte VZV DNA'sı polimeraz zincir reaksiyonu (PCR) pozitif bulundu. Valasiklovir 3x1 gr 14 gün süreyle uygulandı ve ardından valasiklovir 2x500 mg ile profilaktik tedaviye başlandı. Daha sonra immunsüpresif tedaviye davam edilmesine rağmen HZ atakları gözlenmedi. Bağışıklık sistemi baskılanmış bireylerde tekrarlayan HZ atağı gelişmesi durumunda profilaktik antiviral tedavi uygulaması gerektiğini düşünmekteyiz. (Türkderm 2011;45:111-4)

🔖

Cite This Article

BAYINDIR, Y., BAYRAM, H. G., ÖZCAN, H. (2022). Prophylactic antiviral treatment in recurrent herpes zoster: a case report. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 45 - Sayı: 2, 111–114. https://ajindex.com/articles/621981

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Öztürkcan S: Herpes zoster (Zona, Gece Yanığı). Dermatoloji. Ed.Tüzün Y, Gürer MA, Serdaroğlu S, O¤uz O, Aksungur VL. 3.bask›. İstanbul, Nobel Tıp Kitapevleri, 2008;607-14
  2. Straus SE, Oxman MN, Schmader KE: Varicella and herpes zoster. Dermatology in general medicine. Ed. Wolff K, Goldsmith LA, Katz SI, G›lchrest BA, Paller AS, Leffell DJ. Seventh edition. New York, McGraw-Hill Companies, 2008;1885-98
  3. Soyuncu S, Berk Y, Eken C, Gulen B, Oktay C: Herpes zoster as a useful clinical marker of underlying cell-mediated immune disorders. Ann Acad Med Singapore 2009;38:136-8
  4. Gnann JW Jr, Whitley RJ: Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-7
  5. Arvin AM: Varicella-zoster virus. Clin Microbiol Rev 1996;9:361-81
  6. Glynn C, Crockford G, Gavaghan D, Cardno P, Price D, Miller J: Epidemiology of shingles. J R Soc Med 1990;83:617-9
  7. Hope-Simpson RE: The nature of herpes zoster:a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20
  8. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices(ACIP). MMWR Recomm Rep 2008;57:1-30
  9. Chien AJ, Olerud JE: Why do so many clinicians believe that recurrent zoster is common? Dermatol Online J 2007;13:2
  10. Chang CM, Woo E, Yu YL, Huang CY, Chin D: Herpes zoster and its neurological complications. Postgrad Med J 1987;63:85-9
  11. Koh MJ, Seah PP, Teo RY: Zosteriform herpes simplex. Singapore Med J 2008;49:59-60
  12. Sandherr M, Einsele H, Hebart H et al: Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:1051-9
  13. Vickrey E, Allen S, Mehta J, Singhal S: Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multipl myeloma patients receiving bortezomib therapy. Cancer 2009;115:229-32
  14. Erard V, Guthrie KA, Varley C et al: One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110:3071-7
  15. Klein A, Miller KB, Sprague K, DesJardin JA, Snydman DR: A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recu